There are considerable drawbacks to oral anticoagulant for monitoring patients at home which should lead family physicians to discuss alternative or enhanced solutions: A cross-sectional study

BMC Cardiovascular Disorders

Volumn 13, Issue , 2013, Pages

  Le Reste, Jean Y ^a   Chiron, Benoit ^a   Le Floch, Bernard ^a   Nabbe, Patrice ^a   Barrais, Marie ^a   Mansourati, Jacques ^b   Cadier, Sébastien ^a   Barraine, Pierre ^a   Lietard, Claire ^b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; THROMBOPLASTIN;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FRANCE; GENERAL PRACTITIONER; HOME MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY PERSONNEL; NURSE; PRIORITY JOURNAL; QUESTIONNAIRE; URBAN RURAL DIFFERENCE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CROSS-SECTIONAL STUDIES; FRANCE; HOME CARE SERVICES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MONITORING, AMBULATORY; NURSES, COMMUNITY HEALTH; PHYSICIANS, FAMILY; QUESTIONNAIRES;

EID: 84883606548     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-13-71     Document Type: Article

References (18)

1. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167:1414-1419.
2. Michel P, Quenon JL, Djihoud A, Tricaud-Vialle S, De Saraquesta AM. Les événements indésirables graves liés aux soins observés dans les établissements de santé. Drees - Ministère des Affaires sociales et de la Santé 2005, Available from: http://www.drees.sante.gouv.fr/les-evenements-indesirables-graves-lies-aux-soins-observes-dans-les-etablissements-de-sante-premiers-resultats-d-une-etude-nationale,4542.html. [cited 2012 Oct 30].
3. Castot A, Haramburu F, Kreft-Jaïs C. Evaluation du risque de iatrogenie medicamenteuse Ministère des Affaires sociales et de la Santé, Available from: http://www.sante.gouv.fr/evaluation-du-risque-d-iatrogenie-medicamenteuse.html. [cited 2012 Oct 30].
4. Goswami B, Tayal D, Chawla R, Mallika V. Pre-analytical factors that influence the interpretation of prothrombin time in the clinical laboratory: one year experience in a super speciality hospital in India. Clin Chim Acta 2009, 410:93-94.
5. Tripodi A, Breukink-Engbers WGM, van den Besselaar AMHP. Oral anticoagulant monitoring by laboratory or near-patient testing: what a clinician should be aware of. Semin Vasc Med 2003, 3:243-254.
6. Chastagner M, Gault M, Lefevre Schmitt N, Chabrerie S, Van Keirsbilck C. Le bon usage des Antivitamines K. Programme Régional de l'Assurance Maladie 2002-2003 urcam limousin. Available from: http://ars.sante.fr/fileadmin/LIMOUSIN/publications/avk_synthese_08aout2003.pdf. [cited 2012 Oct 30].
7. Lucas-barbre C. Surveillance biologique du traitement par antivitamines-K: enquête sur la coordination des soins entre les professionnels de santé concernés, dans le Finistère Nord. Service universitaire de documentation 2006. Available from: http://www.sudoc.fr/10802248X. [cited 2012 Oct 30].
8. Awad MA, Selim TE, Al-Sabbagh FA. Influence of storage time and temperature on international normalized ratio (INR) levels and plasma activities of vitamin K dependent clotting factors. Hematology 2004, 9:333-337.
9. van Geest-Daalderop JHH, Mulder AB, Boonman-de Winter LJM, Hoekstra MMCL, van den Besselaar AMHP. Preanalytical variables and off-site blood collection: influences on the results of the prothrombin time/international normalized ratio test and implications for monitoring of oral anticoagulant therapy. Clin Chem 2005, 51:561-568.
10. Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012, 379(9813):322-334.
11. Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS. Effect of home testing of international normalized ratio on clinical events. New Engl J Med 2010, 363:1608-1620.
12. Haute Autorité de Santé Traitement par antivitamines K. HAS. 2012, Available from: http://www.has-sante.fr/portail/jcms/c_1168574/traitement-par-antivitamines-k. [cited 2012 Oct 30], Haute Autorité de Santé.
13. van den Besselaar AM, Meeuwisse-Braun J, Schaefer-van Mansfeld H, van Rijn C, Witteveen E. A comparison between capillary and venous blood international normalized ratio determinations in a portable prothrombin time device. Blood Coagul Fibrinolysis 2000, 11(6):559-562.
14. Schirmer SH, Baumhäkel M, Neuberger H-R, Hohnloser SH, van Gelder IC, Lip GY, Böhm M. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol 2010, 56:2067-2076.
15. Andersson S, Björholt I, Nilsson GH, Krakau I. Resource consumption and management associated with monitoring of warfarin treatment in primary health care in Sweden. BMC family practice 2006, 7:67.
16. Veltkamp R, Hacke W. New oral anticoagulants in atrial fibrillation. Nervenarzt 2011, 82:180-189.
17. Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 2011, 130:46-58.
18. Saint Germes M. Enquête sur la coordination des principaux professionnels de santé (médecin traitant, infirmière libérale, biologiste) dans la surveillance biologique des patients sous antivitamine K en région Midi-Pyrénées. Service universitaire de documentation; 2008. Available from: http://www.sudoc.fr/136252893 [cited 2012 Oct 30].